Tumour necrosis factor and lipopolysaccharide can promote a regulated form of necrosis, called necroptosis, upon inhibition of caspase activity in cells expressing receptor-interacting serine/threonine kinase (RIPK)3. Because inhibitors of RIPK1 kinase activity such as necrostatin-1 block necroptosis in many settings, RIPK1 is thought to be required for activation of RIPK3, leading to necroptosis. However, here we show that, although necrostatin potently inhibited tumour necrosis factor-induced, lipopolysaccharide-induced and polyIC-induced necroptosis, RIPK1 knockdown unexpectedly potentiated this process. In contrast, RIPK3 knockdown potently suppressed necroptosis under the same conditions. Significantly, necrostatin failed to block necroptosis in the absence of RIPK1, indicating that its ability to suppress necroptosis was indeed RIPK1-dependent. These data argue that RIPK1 is dispensable for necroptosis and can act as an inhibitor of this process. Our observations also suggest that necrostatin enhances the inhibitory effects of RIPK1 on necroptosis, as opposed to blocking its participation in this process.
Introduction
Although necrosis generally results from severe pathological insults, recent studies have suggested that certain membrane receptor ligands, such as tumour necrosis factor (TNF) and Fas, can promote a form of programmed necrosis, also called necroptosis, in some cell types [1] [2] [3] [4] [5] [6] . TNF and Fas receptor stimulation can promote apoptosis via TRADD/FADD-dependent recruitment of caspase-8 to the intracellular death domains of these receptors [7, 8] . However, TNF or Fas receptor engagement can result in necroptosis, in cells that express receptor-interacting serine/threonine kinase (RIPK)3, when receptor stimulation occurs in the presence of pharmacological or viral-derived caspase inhibitors [1, 9, 10] . In cells lacking RIPK3, inhibition of caspase activity completely blocks TNFinduced cell death, but in RIPK3-expressing cells it results in a necrotic-like mode of cell death. Similarly, targeted disruption of the CASP-8 or FADD loci leads to embryonic lethality, owing to ectopic necrosis early in development [11] [12] [13] [14] . Thus, necroptosis represents an alternative mode of cell death that is triggered in RIPK3-expressing cells when caspase activation is interfered with. The redirecting of TNF-initiated or Fas-initiated signals could be beneficial for certain pathogens, e.g. through termination of TNF-dependent proinflammatory responses. Alternatively, TNF-induced necroptosis could act as a safeguard against pathogens that interfere with proinflammatory signalling, by killing cells harbouring such pathogens [15] [16] [17] . At present, necroptosis is thought to result from TNF receptor (TNFR)-dependent, toll-like receptor (TLR)4-dependent or TLR3-dependent activation of RIPK1, leading to phosphorylation, oligomerization and activation of RIPK3 [5, [17] [18] [19] . Deregulated RIPK3 activation, in turn, leads to phosphorylation and oligomerization of mixed-lineage kinase domainlike (MLKL) [20] [21] [22] , which triggers relocalization of the latter to the plasma membrane [21, 22] . Oligomerized MLKL promotes necroptosis by a mechanism that has yet to be fully resolved, but may involve activation of TRPM7 calcium channels [21] or direct permeabilization of the plasma membrane by MLKL oligomers [22] . RIPK3 appears to be essential for necroptosis, as cells lacking this kinase fail to engage in this process [11, 12, 14, 17] .
Although it is widely believed that RIPK1 is required for phosphorylation and activation of RIPK3 in the TNF pathway to necroptosis as well as in other contexts [3, 17] , the role that RIPK1 plays in necroptosis is unclear. A key reason why RIPK1 kinase activity is thought to be required for necroptosis is that necrostatin-1, a RIPK1 inhibitor, potently inhibits this mode of cell death in numerous contexts [23] [24] [25] . Indeed, necrostatin-1-inhibitable cell death has effectively become a defining characteristic of necroptosis. Furthermore, because necroptosis appears to occur under certain pathological conditions in vivo, necrostatin analogues are currently undergoing evaluation as possible therapeutic agents [26, 27] . However, inhibition of necroptosis by RIPK1 inhibitors may not necessarily reflect a requirement for RIPK1 kinase activity for this mode of cell death to proceed. Inhibition of RIPK1 kinase activity could alter the function of this molecule to generate a dominant-negative inhibitor of necroptosis. In this regard, it is highly pertinent to note that, whereas RIPK3 À/À mice are viable [28] , RIPK3 kinase-dead knock-in mice are embryonic lethal, apparently because of the ability of the kinase-dead form of RIPK3 to bind FADD and promote ectopic caspase-8-dependent apoptosis [29] . Thus, the wild-type and kinase-dead forms of RIPK3 show radically different binding characteristics and have different functions as a consequence. Therefore, it is also possible that the kinase-inhibited form of RIPK1 (as a consequence of necrostatin-1 treatment) has a radical alteration in its conformation, such that it now acts as an inhibitor of necroptosis. Indeed, there are a number of observations at odds with the view that RIPK1 is a positive regulator of necroptosis. First, several reports have suggested that RIPK1 is dispensable for necroptosis in some settings [30] [31] [32] [33] . Second, whereas RIPK3 À/À mice are viable [28] , targeted inactivation of RIPK1 is lethal, most likely due to enhanced apoptosis as a consequence of reduced RIPK1-dependent nuclear factor-jB (NF-jB) activation [13, 34] . However, targeted inactivation of CASP-8, which should suppress ectopic apoptosis generated through loss of RIPK1, fails to rescue the RIPK1 knockout phenotype [35, 36] . The latter observation is at odds with the idea that RIPK1 À/À animals die as a result of excessive apoptosis. Furthermore, deletion of RIPK3 also fails to suppress lethality resulting from RIPK1 loss [35] [36] [37] , whereas RIPK3 loss does suppress lethality resulting from CASP-8 or FADD deletion, suggesting that the latter animals die because of excessive necroptosis [11, 12, 14] . Rather surprisingly, three recent reports have suggested that combined loss of RIPK3 and CASP-8 blocks the lethal effect of RIPK1 deletion [35] [36] [37] . These observations suggest that RIPK1 acts simultaneously to repress caspase-8-dependent apoptosis and RIPK3-dependent necroptosis. Therefore, rescue of RIPK1 null animals requires the elimination of both CASP-8 (to block apoptosis) and RIPK3 (to block necroptosis). These data suggest that the role of RIPK1 as a positive regulator of necroptosis requires further clarification. Here, we explored the requirement for RIPK1 for TNF-induced, lipopolysaccharide (LPS)-induced and polyIC-induced necroptosis, and demonstrate that not only is RIPK1 dispensable for this process, but also that RIPK1 knockdown leads to greatly accelerated necroptosis. Moreover, whereas the RIPK1 inhibitor necrostatin-1 blocked necroptosis in the presence of RIPK1, it failed to do so when RIPK1 expression was silenced. Collectively, these data suggest that RIPK1 participates in necroptosis as an inhibitor of this process, a function that is strongly enhanced via necrostatin-1, most likely through conversion of RIPK1 into a dominant-negative inhibitor of RIPK3 activation.
zVAD-fmk resulted in TNF-induced necroptosis of L929 cells within 5-6 h of receptor stimulation. TNF/ zVAD-induced necroptosis was strongly suppressed by the RIPK1 inhibitor necrostatin, suggesting that the kinase activity of RIPK1 is required for necroptosis (Fig. 1C) . Furthermore, knockdown of RIPK3 or MLKL also readily protected cells from TNF-induced necroptosis (Fig. 1D) . Thus, upon inhibition of caspase activity, TNF induces necroptosis in a RIPK3-dependent and MLKL-dependent manner, as recently reported [20] .
Silencing of RIPK1 expression potentiates TNFinduced necroptosis
Because necrostatin is a RIPK1 inhibitor [23, 24, 38] , it is widely believed that RIPK1 kinase activity is required to promote RIPK3 activation and necroptosis [5, [17] [18] [19] . However, an alternative interpretation of the effects of necrostatin is that the kinase-inhibited form of RIPK1 could act as a dominant-negative inhibitor of necroptosis. To clarify the requirement for RIPK1 for TNF-induced necroptosis, we silenced the expression of RIPK1 and explored the impact of this on TNF/zVAD-induced necroptosis in L929 cells. However, not only did RIPK1 knockdown fail to protect cells from TNF-induced necroptosis, but silencing of RIPK1 expression clearly potentiated this process ( Fig. 2A,B) . In contrast, RIPK3 knockdown robustly protected cells from TNF-induced necroptosis ( Fig. 2A,B) . Potentiation of TNF-induced necroptosis as a consequence of RIPK1 knockdown was observed over a wide range of TNF concentrations (Fig. 2C) . Thus, in opposition to the idea that RIPK1 kinase activity is required for necroptosis, these data suggest that RIPK1 acts as an inhibitor of this process in certain contexts.
To exclude the possibility that RIPK1 knockdown enhanced TNF/zVAD-induced cell death in a manner unrelated to the necroptotic pathway, we also investigated whether the enhanced necroptosis seen upon RIPK1 knockdown was RIPK3-dependent. However, sensitization to TNF/zVAD-induced necrosis caused by RIPK1 knockdown was completely abolished by simultaneous RIPK3 knockdown, arguing that death in this context was necroptotic ( Fig. 2A,B) . Several studies have shown that RIPK3 forms oligomers under necroptotic conditions, and these can be detected as higher molecular mass forms on nondenaturing SDS/ PAGE. As demonstrated in Fig. 2D , we also confirmed that the formation of RIPK3 oligomers in response to TNF/zVAD treatment was enhanced by RIPK1 knockdown.
To explore whether TNF-induced necroptosis was also RIPK1-independent in another cell type, we used primary mouse embryonic fibroblasts (MEFs), which also underwent necroptosis in response to TNF/zVAD treatment (Fig. 3A) . TNF/zVAD-induced necrosis in MEFs was also inhibited by necrostatin, again suggesting a requirement for RIPK1 kinase activity (Fig. 3B,  C) . However, as observed in L929 cells, RIPK1 knockdown in MEFs failed to protect cells from TNF/ zVAD-induced necroptosis, and resulted in higher levels of necroptosis in response to TNF/zVAD treatment (Fig. 4) . Once again, TNF/zVAD-induced necroptosis was robustly inhibited by RIPK3 knockdown in the same context (Fig. 4) , and the enhanced necroptosis seen as a consequence of RIPK1 knockdown was blocked by concurrent silencing of RIPK3 expression (Fig. 4) .
These observations suggest that RIPK1 is a negative rather than a positive regulator of necroptosis, whereas RIPK3 is indispensable for this process.
RIPK1 is dispensible for LPS-induced and polyICinduced necroptosis
Because necroptosis can also be invoked in response to LPS/TLR4 stimulation in the presence of caspase inhibitors, we next explored whether this form of necroptosis also required RIPK1 and/or RIPK3. As shown in Fig. 5A , LPS induced robust necroptosis in RAW macrophages in the presence of zVAD-fmk that was efficiently blocked by necrostatin, as expected. However, silencing of RIPK1 expression failed to block LPS/zVAD-induced necroptosis, and again resulted in greatly accelerated necroptosis, whereas RIPK3 knockdown was protective (Fig. 5B) . We also observed increased formation of RIPK3 oligomers in the absence of RIPK1 following LPS/zVAD treatment (Fig. 5C ). As we observed in the context of TNFinduced necroptosis, the enhanced LPS-induced necroptosis seen after RIPK1 knockdown was completely abolished through concurrent RIPK3 knockdown (Fig. 5B) . We also confirmed the dramatic sensitization to LPS/zVAD-induced necroptosis following RIPK1 knockdown over a range of LPS concentrations (Fig. 5D) .
Treatment with the TLR3 ligand polyIC also promotes necroptosis [32] . Therefore, we also explored whether RIPK1 was dispensable for necroptosis in this setting. We found that RAW macrophages were relatively resistant to polyIC-induced necroptosis in the presence of endogenous RIPK1, even at high concentrations of polyIC (Fig. 6A) . However, RIPK1 knock-down greatly sensitized RAW cells to polyIC-induced necroptosis, whereas RIPK3 knockdown did not (Fig. 6A ). Once again, the increased sensitivity to polyIC-initiated necroptosis seen upon RIPK1 knockdown was abolished through simultaneous RIPK3 knockdown (Fig. 6A ). Sensitization to polyIC- 
Untreated TNF TNF zVAD . At the indicated time points, cell death was analysed by morphological assesment. RIPK1 expression and RIPK3 expression were determined by immunoblotting. (B) Phase contrast images of L929 cells treated as in (A) with the indicated siRNAs, and then exposed to TNF/zVAD for 10 h. (C) L929 cells were electroporated with the indicated siRNAs. After 48 h, cells were either left untreated or treated with zVAD (5 lM) for 1 h, and this was followed by addition of TNF to the indicated concentrations. After a further 6 h, cell death was analysed by PI staining. RIPK1 and RIPK3 expression levels were determined by immunoblotting. (D) L929 cells were electroporated with the indicated siRNAs. After 48 h, cells were treated with zVAD (10 lM) for 1 h, and this was followed by addition of TNF to 500 pgÁmL À1 . At the indicated time points, cell death was analysed by morphological assessment, and RIPK3 oligomerization was analysed by nonreducing SDS/PAGE. A minimum of 300 cells were counted per treatment. NS, non-specific control oligo.
induced necroptosis, as a consequence of RIPK1 knockdown, was observed over a range of polyIC concentrations (Fig. 6B) .
Necrostatin blocks necroptosis only in the presence of RIPK1
The fact that RIPK1 knockdown failed to block necroptosis in response to TNF, LPS or polyIC treatment, but that the RIPK1 inhibitor necrostatin did, suggested either that necrostatin was operating in an off-target manner, or that the role of RIPK1 in necroptosis is more complex than currently understood. To resolve whether necrostatin has an off-target effect on necroptosis, we investigated whether this inhibitor still protected cells from necroptosis upon RIPK1 knockdown. Whereas necrostatin efficiently blocked TNF/zVAD-induced necroptosis in L929 cells in the presence of RIPK1 (Fig. 7A) , it failed to do so upon RIPK1 knockdown (Fig. 7B-D) . Indeed, as demonstrated earlier, RIPK1 knockdown greatly sensitized cells to necroptosis, and this effect was not reversed by necrostatin (Fig. 7B,D) . However, RIPK3 knockdown concurrently with RIPK1 knockdown did protect cells from TNF/ zVAD-induced necroptosis (Fig. 7B,C) . Similar data were obtained in a time course analysis, which clearly showed that necrostatin failed to block TNF/ zVAD-induced necroptosis in the absence of RIPK1 expression at any of the time points examined (Fig. 8A,B) . RIPK1 associates with a necroptosis-inducing complex, 'the necrosome', composed of caspase-8, RIPK1, and RIPK3, which is thought to serve as the MLKL activation platform [5, 39] . Necrostatin is thought to prevent necroptosis by inhibiting RIPK1-mediated RIPK3 phosphorylation and oligomerization, which are required for MLKL activation downstream. We therefore investigated whether RIPK1 was required for the ability of necrostatin to prevent RIPK3 oligomerization. As can be seen in Fig. 8C , RIPK1 knockdown accelerated the formation of RIPK3 oligomers in response to TNF/zVAD, once again suggesting that RIPK1 was dispensable for RIPK3 activation. Furthermore, whereas necrostatin efficiently blocked the formation of RIPK3 oligomers in the presence of RIPK1, it failed to do so upon knockdown of the latter (Fig. 8C) . These data suggest that whereas the kinase-inhibited form of RIPK1 can prevent necroptosis by suppressing RIPK3 oligomerization, RIPK1 is dispensable for RIPK3 activation.
Discussion
Here, we have shown that RIPK1 is dispensable for necroptosis induced by TNF and by the TLR ligands LPS and polyIC. Furthermore, RIPK1 knockdown greatly accelerated necroptosis induced by all of these stimuli, arguing that this kinase acts as an inhibitor of this process, a property that is potentiated by the RIPK1 inhibitor necrostatin. Consistent with this idea, whereas necrostatin efficiently blocked necroptosis when RIPK1 was present, it failed to have any effect when RIPK1 was absent. These data argue that necrostatin blocks necroptosis in an RIPK1-dependent manner, most likely through enhancing the inhibitory Nonreducing C D effects of RIPK1 on this mode of cell death. Importantly, the accelerated necroptosis seen upon RIPK1 knockdown was fully RIPK3-dependent. Collectively, these data argue that RIPK1 can function as a suppressor of necroptosis, and that RIPK1 inhibitors block this mode of cell death in an unexpected way. Previous studies have suggested that RIPK1 is required for TNF-induced necroptosis in HT-29 cells [3] and Fas-induced necroptosis in Jurkat cells [9] . Indeed, RIPK1 knockdown in HT-29 cells protected cells from necroptosis induced by coexposure to TNF, smac mimetic, and zVAD [3] . Similarly, RIPK1-deficient Jurkat cells failed to engage in necroptosis in response to Fas ligand and zVAD [9] . These data demonstrate that particular cell types may require RIPK1 for necroptosis, but what dictates this requirement remains obscure. However, much of the evidence that RIPK1 is required for necroptosis revolves around the use of RIPK1 inhibitors, rather than knockdown or gene inactivation of RIPK1. Therefore, the actual requirement for RIPK1 in many instances of necroptosis should be re-evaluated, as we have now demonstrated. A major difference between inhibition of RIPK1 kinase activity by necrostatin and RIPK1 knockdown is that necrostatin does not impede RIPK1-dependent NF-jB activation, as the kinase activity of the latter is not required for its role as a scaffold for IKKc/NEMO recruitment. In contrast, RIPK1 knockdown eliminates both its scaffold function in NF-jB activation and its kinase activity. This raises the possibility that RIPK1-dependent gene expression events could, at least in principle, contribute to its ability to suppress necroptosis in the presence of necrostatin. Alternatively, necrostatin could promote a conformational change in RIPK1 that permits the necrostatin-inhibited form of RIPK1 to act in a dominant-negative fashion, perhaps through binding and inhibiting RIPK3 or MLKL. Recently, Dixit et al. have demonstrated that knock-in of kinase-dead RIPK3 results in embryonic lethality, owing to excessive yolk sack apoptosis [29] . Unlike wild-type RIPK3, the kinase-dead RIPK3 has the ability to associate with FADD and caspase-8, thus driving excessive apoptosis.
It is therefore highly plausible that RIPK1, in its necrostatin-bound kinase-inhibited form, is a potent inhibitor of necroptosis because of altered binding properties and not because of the loss of its kinase activity as such.
As mentioned earlier, very recent genetic studies also provide strong support for the idea that RIPK1 is a suppressor of both RIPK3-dependent necroptosis and caspase-8-dependent apoptosis [35] [36] [37] . Deletion of RIPK1 is lethal at birth [34] , but this effect is only partly rescued by concurrent deletion of TNFR1 [40] . However, three recent studies have shown that lethality resulting from RIPK1 loss is completely rescued through concurrent deletion of CASP-8 and RIPK3, suggesting that RIPK1 À/À animals because of both excessive apoptosis and RIPK3-dependent necroptosis [35] [36] [37] . The latter observations support the idea that RIPK1 is an important suppressor of RIPK3-dependent necroptosis in vivo. Furthermore, during review of this manuscript, an additional study also reported that RIPK1 concurrently suppresses both apoptosis and necroptosis in epithelial tissues [41] . The latter study demonstrated that epidermal-specific loss of RIPK1 triggered keratinocyte apoptosis and necroptosis, and that this was attenuated by combined RIPK3 loss. Furthermore, kinase-inactive RIPK1 knock-in delayed inflammation resulting from FADD loss. This suggests that the kinase activity of RIPK1 is required for the pathology seen or, alternatively, that the kinase-inactive form of RIPK1 acts as a dominant-negative inhibitor of necroptosis and inflammation in vivo.
In the absence of RIPK1, it remains unclear whether RIPK3 undergoes autoactivation under necroptotic conditions or whether an upstream kinase is involved. The presence of an RHIM domain-containing adaptor may be essential to facilitate recruitment of RIPK3 to the stimulated receptor. In the absence of RIPK1, it is possible that an as yet unidentified RHIM adaptor facilitates RIPK3 recruitment to TNFR. Alternatively, deregulated activation of an as yet unidentified kinase may activate RIPK3 in the absence of RIPK1. Indeed, RIPK1 has been shown to be dispensable for necropto- sis induced by LPS or viral infection but dependent on the RHIM adaptors TRIF and DAI, respectively [10, 32] . Our data not only confirm that RIPK1 is dispensable for necroptosis in these settings, but also suggest that it functions in these pathways as an inhibitor, to desensitize the latter receptors from necroptosis.
In conclusion, we have shown that RIPK1 acts as an inhibitor of TNF-induced and TLR-induced necroptosis, and that necrostatin blocks this mode of cell death in an unexpected way, most likely through enhancing the suppressive effects of RIPK1 on necroptosis.
Experimental procedures

Materials
The following antibodies were used: anti-RIPK1 (BD, UK), anti-RIPK3 (ProSci, UK), and anti-actin (ImmunO, UK). Recombinant murine TNF-a was purchased from Roche. zVAD-fmk was from Bachem, and necrostatin-1, polyIC and LPS were from Sigma Ireland.
Cell culture
L929 cells were cultured in RPMI medium (Gibco, UK) supplemented with 5% fetal bovine serum. MEFs and RAW macrophages were cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum. Cells were cultured at 37°C in humidified atmosphere with 5% CO 2 .
Cell death assays
Cells were plated at 2 9 10 5 cells per well in six-well plates, and treated as indicated 24 h later. In general, cells were pretreated with the indicated reagents, and this was followed by addition of TNF, LPS or polyIC 1 h later. Necroptosis was enumerated on the basis of cell morphology (cell swelling, detachment from the plate, and membrane rupture) and by flow cytometry-based annexin V-propidium iodide (PI) staining. A minimum of 300 cells were counted in each treatment. Each assay was repeated a minimum of three times. 
Western immunoblotting
Cell lysates were prepared by the use of SDS/PAGE loading buffer, and electrophoresed on 8-12% SDS/PAGE gels. Protein expression was examined by western immunoblotting. b-Mercaptoethanol was excluded from sample buffer for nonreducing conditions.
RNA interference
To silence mouse RIPK-1, mouse RIPK3 and mouse MLKL expression in L929 cells, MEFs, and RAW macrophages, cells were transfected with siRNA by the use of nucleofection (Amaxa), according to the manufacturer's instructions. Cells were incubated with siRNA for 48 h, and this was followed by the indicated treatment. siRNA sequences were as follows: mouse RIPK1#1 sense, 5 0 -CCACUAGUCUGACU GAUGA-3 0 ; mouse RIPK1#2 sense, 5 0 -GAGGAUAUUC UCAGGCUUCAGGUCCUU-3 0 ; mouse RIPK3#1 sense, 
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